SCHEMBL4933092

SCHEMBL4933092

NC1N=CC=CC1(N)Cc1cccc(-c2cccnc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.44
▸ PRMT6 Q96LA8 1/20 0.44
▸ BACE1 P56817 3/20 0.40
▸ MKNK1 Q9BUB5 2/20 0.40
▸ MKNK2 Q9HBH9 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ PSIP1 O75475 1/20 0.40
▸ AXL P30530 1/20 0.40
▸ CYP2A6 P11509 2/20 0.40
▸ KDM1A O60341 1/20 0.39
▸ LOXL2 Q9Y4K0 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP19A1 P11511 3/20 0.36
▸ CYP11B1 P15538 3/20 0.36
▸ CYP11B2 P19099 3/20 0.36
▸ DHFR P00374 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ HCRTR1 O43613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931182 0.89 BACE1 (0.38) EPHX2PRMT6BACE1CYP2A6DHFR
SCHEMBL4938118 0.86 AGXT (0.42) BACE1KDM1ACYP19A1CYP11B1CYP11B2
SCHEMBL4939325 0.82 BACE1 (0.45) BACE1MKNK1MKNK2CYP1A2CYP3A4
SCHEMBL4934778 0.82 CYP11B1 (0.46) ALDH1A1CYP1A2CYP3A4CYP19A1CYP11B1
SCHEMBL4941227 0.77 BACE1 (0.44) BACE1KDM1A
SCHEMBL4935935 0.74 HSD17B10 (0.37) HCRTR1HCRTR2
SCHEMBL4930683 0.73 KDM4E (0.37) ALDH1A1
SCHEMBL4938952 0.73 MEN1 (0.45) MEN1ALDH1A1CYP19A1CYP11B1CYP11B2
SCHEMBL4937791 0.72 MAOB (0.46) KDM1AALDH1A1DHFR
SCHEMBL30612277 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof ASTRAZENECA AB (SE) 2008-11-20 — — US claimed
EP-1831170-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF AstraZeneca AB (SE) 2007-09-12 — — EP claimed
WO-2006065204-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF ASTRAZENECA AB (SE) 2006-06-22 — — WO claimed
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof ASTRAZENECA AB (SE) 2008-11-20 — — US disclosed
EP-1831170-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF AstraZeneca AB (SE) 2007-09-12 — — EP disclosed
WO-2006065204-A1 SUBSTITUTED AMINOPYRIDINES AND USES THEREOF ASTRAZENECA AB (SE) 2006-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287399-A1 Substituted Aminopyridines and Uses Thereof PSEN2, SLC1A2, PSEN1 EPHX2 3101/4885PRMT6 400/4885BACE1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback